• Users Online: 5
  • Print this page
  • Email this page


 
 Table of Contents  
SHORT COMMUNICATION
Year : 2019  |  Volume : 10  |  Issue : 3  |  Page : 134-139

Middle East and North Africa region guidelines for the management of type 2 diabetes


1 Diabetic Association of Pakistan and WHO Collaborating Centre, Baqai Medical University, Karachi, Pakistan
2 Department of Medicine, Baqai Medical University, Karachi, Pakistan
3 Research, Baqai Institute of Diabetology and Endocrinology, Baqai Medical University, Karachi, Pakistan; Department of Biochemistry, Baqai Medical University, Karachi, Pakistan

Date of Web Publication27-Aug-2019

Correspondence Address:
Prof. Abdul Basit
Department of Medicine, Baqai Institute of Diabetology and Endocrinology, Baqai Medical University, Karachi.
Pakistan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jod.jod_43_18

Rights and Permissions
  Abstract 

The International Diabetes Federation is divided into seven regions, Africa (AFR), Europe (EUR), Middle East and North Africa (MENA), North America and Caribbean (NAC), South and Central America (SACA), South East Asia (SEA) and Western Pacific (WP), with the aim of enhancing the work of national diabetes associations and strengthening the collaboration between them. In the MENA region, adult population (aged 20–79 years) was estimated 387 million in 2015 from which 35.4 million were suffering from diabetes and is expected to increase up to 72.1 million in 2040. Of the 35.4 million people affected by diabetes, nearly 40.6% were estimated to be undiagnosed. Therefore, at considerable risk of diabetes complications and poor health outcomes. The importance of glycemic control in preventing and delaying the progression of diabetes complications is well well-known. Diabetes poses extreme financial load to diabetic subjects. Local guidelines help to upgrade management strategies. It provides ideas for health care providers to improve quality of life of patient. Guidelines were prepared reviewing the literature, reviewing the available guidelines, consultative meetings between the experts and country representatives from the region.

Keywords: Complications of diabetes, non-pharmacological management, pharmacological management, referral criteria


How to cite this article:
Shera A S, Basit A, Fawwad A. Middle East and North Africa region guidelines for the management of type 2 diabetes. J Diabetol 2019;10:134-9

How to cite this URL:
Shera A S, Basit A, Fawwad A. Middle East and North Africa region guidelines for the management of type 2 diabetes. J Diabetol [serial online] 2019 [cited 2019 Sep 16];10:134-9. Available from: http://www.journalofdiabetology.org/text.asp?2019/10/3/134/265417




  Introduction Top


The International Diabetes Federation (IDF) is a federation of over 230 national diabetes associations in 170 countries and territories. The IDF is divided into seven regions, with the aim of enhancing the work of national diabetes associations and strengthening the collaboration between them. IDF’s national diabetes associations are divided into the following regions: Africa, Europe, Middle East and North Africa (MENA), North America and Caribbean, South and Central America, South East Asia and Western Pacific.[1]

In IDF, there are 24 diabetic organisations are register of 19 countries.[2],[3] In the MENA region, adult population (aged 20–79 years) was estimated 387 million in 2015 from which 35.4 million were suffering from diabetes and is expected to increase up to 72.1 million in 2040. Of the 35.4 million people affected by diabetes, nearly 40.6% were estimated to be undiagnosed and therefore at a considerable risk of diabetes complications and poor health outcomes.[4] The importance of glycaemic control in preventing and delaying the progression of diabetes complications is well well-known.[5] Diabetes poses extreme financial load to diabetic patients. Local guideline helps to upgrade management strategies. It provides ideas for health-care providers to improve the quality of life of the patient. For developing the regional guideline, regional authorities to discuss with the responsible person (care leavers) this co-work to produce a meaningful guideline that reflects the need of care leavers. The effectiveness of guideline is proper which defines quality differently among doctors, payers and managers.[6]


  Referral Criteria for Different Levels of Care Top


For referral criteria, primary, secondary and tertiary care plays an important role in the management of diabetes. The primary physician is the first level of contact for individuals, families and communities, in the health-care system. Primary health-care facility for diabetic patients is mostly provided by certified diabetes doctors and educators. The secondary care is based on multidisciplinary team supervised by a physician having post-graduate qualification or specialised training in diabetes care. The team includes qualified and trained diabetes educators and diabetic foot care assistants. Tertiary care level is a university-based teaching hospital consisting of an outpatient and inpatient integrated care also with research and education programmes. Routine integrated care involves the patient, physician with special interest in diabetes, clinical nurse specialist or educators trained in diabetes, dieticians, diabetic foot care assistants and/or podiatrists. In all levels of care, proper record maintenance for all treated diabetic patients is advisable [Table 1],[Table 2],[Table 3],[Table 4].
Table 1: Diagnostic criteria[7]

Click here to view
,
Table 2: Risk assessment for diabetic individual of region

Click here to view
,
Table 3: Glycaemic targets

Click here to view
,
Table 4: University of Texas diabetic foot ulcer classification system

Click here to view



  Non-Pharmacological Management of Diabetes Top


Lifestyle modifications (LSM) are an important and foremost pillar of management of diabetes. Unbalanced eating habits and unsatisfactory physical activity are main contributors to the development of diabetes.[8],[9] Intake of balanced and safe food, number of meals and proper calculation of energy/caloric requirement plays a vital role in maintaining normoglycaemia. Physical activity like 30min walk 5 days a week can result in adequate benefits in metabolic control, energy expenditure, better work capabilities, feeling of wellbeing and improvement in cardiovascular risk.[10],[11] Education of people with diabetes about the management of hypoglycaemia and hyperglycaemia as well as self-monitoring of blood glucose, knowing about the signs and symptoms of foot problems and awareness of sick day rules prevents the patients from acute emergencies.


  Pharmacological Management of Diabetes Top


LSM and pharmacological management are most important initial steps in the management of Type 2 diabetes [Figure 1].
Figure 1: Middle East and North Africa guideline for the management of type 2 diabetes. DPP IV: Dipeptidyl peptidase IV, GLP 1: Glucagon-like peptide 1, NPH: Neutral protamine Hagedorn, TZD: Thiazolidinedione, SGL2: Sodium–glucose cotransporter 2 inhibitors

Click here to view



  Sensitisers Top


Metformin

Along with LSM metformin is considered as a first-line drug, irrespective of their baseline body mass index (BMI).[12],[13],[14],[15],[16],[17],[18] If metformin is unbearable or contraindicated, DPP4 Inhibitors, sulphonylureas (SUs) or insulin can be used alternatively.[19] Mostly metformin is well tolerated, but common adverse effects are nausea, anorexia, diarrhoea and metallic taste which can be reduced if it is taken with meals. If metformin is contraindicated or unable to achieve normoglycaemia, then a combination therapy is preferred or second-line drugs are prescribed.

Sulphonylureas

SUs decreases plasma glucose levels by enhancing insulin secretion, with an average A1c reduction of 1.5%.[20] The major side effect is hypoglycaemia.

Thiozolidinedione

These insulin sensitisers are peroxisome proliferators-activated receptor gamma agonist.[20]

The major side effects include oedema, weight gain, the risk of congestive heart failure and increased risk of fractures. This significantly limits their clinical use.[21]


  Secretagogues Top


Dipeptidyl peptidase IV inhibitors

Dipeptidyl peptidase IV inhibitors (DPP-4 inhibitors) lower HbA1c by approximately 0.6%–1.0% and are weight neutral.[20] DPP-4 inhibitors have proven efficacy when combined with metformin, sulphonylurea or both metformin and sulphonylurea.[20] They carry low risk of hypoglycaemia.

Glucagon-like peptide 1 agonists

The incretin hormone glucagon-like peptide 1 is known for the “incretin effect.” They facilitate insulin release in the state of hyperglycaemia.[22] They also suppress pancreatic glucagon output, retard gastric emptying and diminish appetite. This usually results in weight reduction.

Repaglinide

It is relatively short-acting stimulators of insulin secretion (<6h). The main risk is hypoglycaemia and weight gain.[23]


  Nutrient Load Reducers Top


Alpha glucosidase inhibitor

The digestion of carbohydrates including starch and table sugar is prevented by alpha-glucosidase inhibitor thus controls post-prandial hyperglycaemia.[24] It can reduce HbA1c by 0.2%[25] Its major side effects are bloating and flatulence.

Sodium–glucose cotransporter 2 inhibitors

These agents reduce HbA1c by 0.5%–1.0%. Their mechanism of action involves inhibiting the sodium-glucose co-transporter inhibitors 2 (SGLT2) in the proximal nephron, thereby reducing glucose reabsorption and increasing urinary glucose excretion by up to 80g/day. Because this action is independent of insulin, SGLT2 inhibitors may be used at any stage of Type 2 diabetes, even after insulin secretion has waned significantly. Additional potential advantages include modest weight loss (~2kg, stabilizing over 6–12 months) and consistent lowering of systolic and diastolic blood pressure in the order of ~2–4/~1–2 mmHg.[26] The common side effect of SGLT2 inhibitor is genital infection, and its incidence raised four-fold in clinical trials.[27]

Insulin

It can be categorised according to either duration of action ranging from rapid-acting insulin to short-acting, intermediate acting, long-acting and very long-acting insulin or their source as human or analogue insulin.[23] Different types of insulin and their duration of action are discussed in [Table 5].
Table 5: Different types of insulin and their duration of action

Click here to view



  Diabetes in Elderly Top


Prevalence of diabetes in older adults has almost doubled in the past 15 years.[28] It is a diverse group which includes active individuals with few complications and co-morbidities on the other hand frail individuals with many co-morbidities and disabling complications. Management of diabetes should be done cautiously with pharmacotherapy and insulin under the supervision of caregivers.


  Acute Emergencies in Type 2 Diabetes Top


Hypoglycaemia and hyperosmolar hyperglycaemic state (HHS) are two common acute emergencies occurring among Type 2 diabetic patients. From which, hypoglycaemia is a common and serious medical condition which usually occurs during the treatment of diabetes. Depending on its clinical presentation it is divided into mild-moderate and severe. Patients at risk of hypoglycaemia should have proper education on recognition, prevention and management of hypoglycaemia.[29] Therefore, patients having a history of hypoglycaemia should carry a snack or meal with adequate carbohydrate and proteins.[30] HHS is associated with significant morbidity and higher mortality than diabetic ketoacidosis and must be diagnosed immediately and managed competently.[31],[32],[33] The clinical picture shows severe dehydration, without ketosis or significant acidosis. Plasma glucose level usually exceeds 600mg/dl. If HHS continues, severe dehydration will lead to seizures, coma and eventually death.[34] The aim of treatment is to treat the underlying cause and to gradually normalise the osmolality with the replacement of fluid and electrolyte losses along with the correction of blood glucose.[35] Underlying cause should be identified to prevent further episodes.


  Microvascular Complications of Diabetes Top


This section is associated with the management of microvascular complications of Type 2 diabetes which are classified as nephropathy, retinopathy and neuropathy. Diabetic nephropathy is the dominant cause of end-stage renal failure. All people with Type 2 diabetes should be screened annually for the presence of microalbuminuria[28],[36] Consider referral to tertiary care if kidney disease is rapidly progressive. Referral is also considered if anaemia, electrolyte imbalance, resistant hypertension, any bone disease or secondary hyperparathyroidism is present.[37] All patients of diabetes should have detailed history of previous eye disease or any pre-existing eye problem. A detailed eye examination is required by an ophthalmologist. If there are no signs of retinopathy than annual eye examination is required. If retinopathy is present, then the frequency of follow-up is suggested by an ophthalmologist.[38],[39] Fundoscopy is recommended in every patient at least once a year or more frequently is indicated. At first visit, examination of peripheral neuropathy is also recommended. Most common presenting complaints are pain, burning and tingling sensations. Almost 50% of patients are usually asymptomatic. Good metabolic control is a pillar of prevention or slow progression of microvascular complications.[28]


  Macrovascular Complications of Diabetes Top


Hypertension

One of the common co-morbidities of diabetes is hypertension which affects majority of diabetic patients and it is a common risk factor for both cardiovascular disease (CVD) and microvascular complications.[40] Blood pressure should be measured at every routine visit. Patients newly diagnosed with systolic blood pressure of ≥140 mmHg or diastolic blood pressure of ≥90mm Hg should have blood pressure confirmed on a subsequent day.[41] Patients with blood pressure >120/80 mmHg should be advised LSM which includes restriction of salt intake and increased consumption of fruits and vegetables. Pharmacotherapy with angiotensin-converting enzyme inhibitors and LSM is initiated if blood pressure persists >140/90 mmgHg.

Peripheral artery disease

Peripheral artery disease (PAD) is defined as any atherosclerotic arterial occlusive disease below the level of the inguinal ligament resulting in a reduction in blood flow to the lower extremity.[42] Identification of PAD is important because its presence results in worst outcome of diabetic foot ulcer which leads to amputation. The patient should be examined annually with appropriate history taking and measurement of ankle brachial index. All patients with diabetes and an ischaemic foot ulcer should receive aggressive cardiovascular risk management, including smoking cessation, treatment of hypertension, control of glycaemia and prescription of a statin as well as low-dose aspirin or clopidogrel.[43]

Dyslipidaemia

It may be manifested by elevation of the total cholesterol, low-density lipoprotein cholesterol and the triglyceride concentrations and/or a decrease in the high-density lipoprotein cholesterol concentration in the blood.[44],[45] Obtain lipid profile at presentation and annually. LSM especially targeting weight reduction in overweight or obese people. All the diabetic patients aged >40 without any other risk factor should be given low dose statin. If other CVD risk factors are present, consider moderate or high dose statins.

Aspirin therapy

Low dose aspirin therapy is an option in people with diabetes with increased CVD risk. This includes a family history of CVD, hypertension, smoking, dyslipidaemia or albuminuria and age >50 years. It may not be recommended in people younger than these ages without additional CVD risk factors. People intolerant to aspirin or if there is any contraindication, clopidogrel is an alternate option.[40],[46]

Diabetic foot

People with diabetes are at increased risk of foot ulcers and amputations. Around 85% of amputations are anticipated by ulcers which are preventable.[47] Annual examination of the foot, assessment of neuropathy and history of claudication or rest pain in lower limb should be taken. For diabetic foot ulcer glycaemic control, appropriate antibiotic coverage, daily dressings, education about the warning signs and regular follow-up is recommended.

Obesity

Obesity and diabetes are usually not universal. There is significant evidence that lifestyle/behavioural interventions for weight reduction, weight reducing medicines or bariatric surgery can improve glycaemic control and reduce the risk of diabetes.

Life style changes

People who are obese and do not have diabetes, can reduce risk of developing diabetes by over 50% by losing of 5% of body weight along with regular exercise and dietary modification, increase consumption of high fibre diet and limiting starchy and oily food.

Pharmacological management of obesity

Phentermine (since 1959) and Orlistat (since 1999) are currently available drugs to decrease obesity. Few newer drugs Liraglutide and Lorcaserin are also affected of weight reduction in an obese population.[48],[49]

Bariatric surgery

Bariatric surgical procedures are used to lose weight by restricting the amount of food the stomach can hold, results in malabsorption of nutrients, or by a combination of both gastric restriction and malabsorption. Indications for bariatric surgery include morbid obesity (BMI >40) or severe obesity (BMI >35) with co-morbidities.[50] Other weight loss surgeries are also performed by using minimally invasive techniques (laparoscopic surgery). Gastric bypass, sleeve gastrectomy, adjustable gastric band and biliopancreatic diversion with duodenal switch are the common bariatric surgery procedures used.[51]


  Diabetic Foot Top


The guidelines for the people with diabetic foot ulcers are not included in this guideline. Please see the link for diabetic foot guideline at; http://iwgdf.org/guidelines-translations.


  Ramadan and Diabetes Top


The guidelines for Ramadan and diabetes are also not included in this guideline. Please see the link for Ramadan and diabetes guideline at; https://www.daralliance. org/daralliance.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
International Diabetes Federation. Available from: http://www.idf.org. [Last accessed on 2017 Apr 26].  Back to cited text no. 1
    
2.
Sherif S, Sumpio BE. Economic development and diabetes prevalence in MENA countries: Egypt and Saudi Arabia comparison. World J Diabetes 2015;6:304–11.  Back to cited text no. 2
    
3.
Available from: http://www.idf.org/membership/MENA. [Last accessed on 2018 Dec 01].  Back to cited text no. 3
    
4.
Available from: http://www.worlddiabetesfoundation.org/sites/default/files/Middle-east.pdf. [Last accessed on 2018 Dec 01].  Back to cited text no. 4
    
5.
Silver B, Ramaiya K, Andrew SB, Fredrick O, Bajaj S, Kalra S, et al. EADSG guidelines: Insulin therapy in diabetes. Diabetes Ther 2018;9:449–92.  Back to cited text no. 5
    
6.
Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelines. BMJ 1999;318:527–30.  Back to cited text no. 6
    
7.
Shera AS, Basit A, Team P. Pakistan’s recommendations for optimal management of diabetes from primary to tertiary care level (PROMPT). Pak J Med Sci 2017;33:1279–83.  Back to cited text no. 7
    
8.
Global Guidelines for Type 2 Diabetes; 2012. Available at: https://www.iapb.org/wp-content/uploads/Global-Guideline-for-Type-2-Diabetes-IDF-2012.pdf. [Last accessed on 2018 Dec 01].  Back to cited text no. 8
    
9.
Ferdi NE, Abla K, Chenchouni H. Effect of socioeconomic factors and family history on the incidence of diabetes in an adult diabetic population from Algeria. Iran J Public Health 2016;45:1636–44.  Back to cited text no. 9
    
10.
Horsch A, Wobmann M, Kriemler S, Munsch S, Borloz S, Balz A, et al. Impact of physical activity on energy balance, food intake and choice in normal weight and obese children in the setting of acute social stress: A randomized controlled trial. BMC Pediatr 2015;15:12.  Back to cited text no. 10
    
11.
Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: A randomized controlled trial. JAMA 2010;304:2253–62.  Back to cited text no. 11
    
12.
Al-Shareef MA, Sanneh AF, Aljoudi AS. Clinical effect of metformin in children and adolescents with type 2 diabetes mellitus: A systematic review and meta-analysis. J Family Community Med 2012;19:68–73.  Back to cited text no. 12
    
13.
Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011;13:221–8.  Back to cited text no. 13
    
14.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin uses in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;4:CD002967.  Back to cited text no. 14
    
15.
Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs 2015;75:1071–94.  Back to cited text no. 15
    
16.
Saenz A, Fernandez EI, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;3:CD002966.  Back to cited text no. 16
    
17.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet 1998;352:854–65.  Back to cited text no. 17
    
18.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.  Back to cited text no. 18
    
19.
Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab 2015;19:577–96.  Back to cited text no. 19
    
20.
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet 2014;383:1068–83.  Back to cited text no. 20
    
21.
Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Fischl AH, et al. Diabetes self-management education and support in type 2 diabetes: A joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Educ 2017;43:40–53.  Back to cited text no. 21
    
22.
Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 2012;55:2929–37.  Back to cited text no. 22
    
23.
Clinical practice guidelines for diagnosis, treatment and follow-up of diabetes mellitus and its complications. Turk JEM 2010;14 Suppl 1:40–6.  Back to cited text no. 23
    
24.
Drent ML, Tollefsen AT, van Heusden FH, Hoenderdos EB, Jonker JJ, van der Veen EA, et al. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: Results of a 24-week double-blind placebo-controlled study. Diabetes Nutr Metab 2002;15:152–9.  Back to cited text no. 24
    
25.
Hölscher C. Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014;221:T31-41.  Back to cited text no. 25
    
26.
Ma J, Liu LY, Wu PH, Liao Y, Tao T, Liu W, et al. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in china. J Diabetes Res 2014;2014:294017.  Back to cited text no. 26
    
27.
Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2017;24:73–9.  Back to cited text no. 27
    
28.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association of Clinical endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary. Endocr Pract 2016;22:84–113.  Back to cited text no. 28
    
29.
Kalra S. Hypoglycaemia in diabetes. J Pak Med Assoc 2014;64:1090–3.  Back to cited text no. 29
    
30.
Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. Lancet 2014;383:1999–2007.  Back to cited text no. 30
    
31.
Savage MW, Dhatariya KK, Kilvert A, Rayman G, Rees JA, Courtney CH, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med 2011;28:508–15.  Back to cited text no. 31
    
32.
Vidyarthi M, Chowdhury TA. Diagnosis and early management of hyperglycaemic emergencies in the emergency department. QJM 2012;105:296–7.  Back to cited text no. 32
    
33.
Chiasson JL, Aris-Jilwan N, Bélanger R, Bertrand S, Beauregard H, Ekoé JM, et al. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. CMAJ 2003;168:859–66.  Back to cited text no. 33
    
34.
Stoner GD. Hyperosmolar hyperglycemic state. Am Fam Physician 2005;71:1723–30.  Back to cited text no. 34
    
35.
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycaemic crises in adult patients with diabetes: A consensus statement from the American Diabetes Association. Diabetes Care 2009;32:1335–43.  Back to cited text no. 35
    
36.
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713–35.  Back to cited text no. 36
    
37.
American Diabetes Association. Microvascular complications and foot care. Sec. 9. Standards of medical care in diabetes 2016. Diabetes Care 2016;39 Suppl 1:S72-80.  Back to cited text no. 37
    
38.
American Diabetes Association. Standards of medical care in diabetes-2017 abridged for primary care providers. Clin Diabetes 2017;35:5–26.  Back to cited text no. 38
    
39.
ICO Guidelines for Diabetic Eye Care; 2017. Available at: http://www.icoph.org/downloads/ICOGuidelinesforDiabeticEyeCare.pdf [Last accessed on 2018 Dec 01].  Back to cited text no. 39
    
40.
Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: Mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) 2011;13:244–51.  Back to cited text no. 40
    
41.
Franklin SS, Thijs L, Li Y, Hansen TW, Boggia J, Liu Y, et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension 2013;61:96471.  Back to cited text no. 41
    
42.
Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608–21.  Back to cited text no. 42
    
43.
European Stroke Organisation, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: The task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2851–906.  Back to cited text no. 43
    
44.
Young MJ, McCardle JE, Randall LE, Barclay JI. Improved survival of diabetic foot ulcer patients 1995–2008: Possible impact of aggressive cardiovascular risk management. Diabetes Care 2008;31:2143–7.  Back to cited text no. 44
    
45.
Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012;19:221–30.  Back to cited text no. 45
    
46.
Xie M, Shan Z, Zhang Y, Chen S, Yang W, Bao W, et al. Aspirin for primary prevention of cardiovascular events: Meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One 2014;9:e90286.  Back to cited text no. 46
    
47.
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005;293:217–28.  Back to cited text no. 47
    
48.
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: A critical review of the evidence. Obes Sci Pract 2017;3:3–14.  Back to cited text no. 48
    
49.
O’Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426–36.  Back to cited text no. 49
    
50.
Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342–62.  Back to cited text no. 50
    
51.
ASMBS. Bariatric Surgery Procedures. Available from: https://www.asmbs org/patients/bariatric-surgery-procedures2016. [Last accessed on 2018 Dec 01].  Back to cited text no. 51
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Referral Criteri...
Non-Pharmacologi...
Pharmacological ...
Sensitisers
Secretagogues
Nutrient Load Re...
Diabetes in Elderly
Acute Emergencie...
Microvascular Co...
Macrovascular Co...
Diabetic Foot
Ramadan and Diabetes
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed78    
    Printed2    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]